AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Betashares Space Industry ETF

9.350

-0.090-0.95%

Volume:11.47K

Turnover:107.39K

Market Cap:40.21M

PE:- -

High:9.430

Open:9.420

Low:9.340

Close:9.440

52wk High:19.000

52wk Low:8.710

Shares:4.30M

Float Shares:4.30M

Volume Ratio:1.36

T/O Rate:0.27%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Rocket Pharmaceuticals Shares Rise After Needham Upgrade

MT Newswires Live

Needham Upgrades Rocket Pharmaceuticals to Buy From Hold, Price Target is $9

MT Newswires Live

Rocket Pharmaceuticals Says FDA Confirms Path to Complete Phase 2 Danon Disease Trial

MT Newswires Live

Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/RCKT.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"RCKT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCKT.AU\",,,,,undefined,":{"symbol":"RCKT.AU","market":"AU","secType":"STK","nameCN":"Betashares Space Industry ETF","latestPrice":9.35,"timestamp":1789539120000,"preClose":9.44,"halted":0,"volume":11470,"delay":0,"changeRate":-0.00953389830508473,"nameEN":"Betashares Space Industry ETF","floatShares":4300000,"shares":4300000,"eps":0,"marketStatus":"Not Yet Opened","change":-0.09,"latestTime":"09-16 16:12:00 AEST","open":9.42,"high":9.43,"low":9.34,"amount":107394,"amplitude":0.009534,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":9.44,"nav":9.559658,"aum":41584512,"bidAskSpread":0,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":1.3577820662383244,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RCKT.AU","preClose":9.35,"auctionPrice":9.41,"auctionVolume":41,"auctionTime":1789592627766,"referenceTime":1789554603098,"auction":1,"marketStatus":"盘前竞价","timestamp":1789592627766}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCKT.AU\",,,,,undefined,":{"symbol":"RCKT.AU","floatShares":4300000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.3577820662383244,"shares":4300000,"dividePrice":0,"high":9.43,"amplitude":0.009534,"preClose":9.44,"low":9.34,"week52Low":8.71,"pbRate":"--","week52High":19,"institutionHeld":0,"latestPrice":9.35,"eps":0,"divideRate":0,"volume":11470,"delay":0,"ttmEps":0,"open":9.42,"prevYearClose":14,"prevWeekClose":9.52,"prevMonthClose":9.57,"prevQuarterClose":12.13,"fiveDayClose":9.89,"twentyDayClose":10.29,"sixtyDayClose":11.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCKT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCKT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCKT.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668798067","title":"Rocket Pharmaceuticals Shares Rise After Needham Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2668798067","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668798067?lang=en_us&edition=fundamental","pubTime":"2026-09-17 02:09","pubTimestamp":1789582178,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals  shares were up almost 2% in Wednesday trading after Needham upgraded the stock to buy from hold, with a price target of $9.Trading volume stood at more than 1.7 million shares, compared with a daily average of about 2 million.Price: 3.48, Change: +0.07, Percent Change: +1.91","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","RCKT","RCKT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667560798","title":"Needham Upgrades Rocket Pharmaceuticals to Buy From Hold, Price Target is $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2667560798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667560798?lang=en_us&edition=fundamental","pubTime":"2026-09-16 18:53","pubTimestamp":1789555985,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals (RCKT) has an average rating of overweight and mean price target of $8.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCKT.AU","BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667337644","title":"Rocket Pharmaceuticals Says FDA Confirms Path to Complete Phase 2 Danon Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667337644","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667337644?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:39","pubTimestamp":1789472373,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals  said Tuesday that it is aligned with the US Food and Drug Administration, or FDA, as it completes its phase 2 trial evaluating RP-A501 to treat Danon disease.The company said that the FDA reviewed data from the first three patients treated under a modified protocol and confirmed continued enrollment of 12 patients dosed at the recalibrated dose.The pivotal study will include 12 male patients, with the first three treated under the modified protocol counting toward the total. Rocket expects to enroll and dose the remaining nine patients by mid-2027.Rocket said it will conduct a primary assessment at 12 months using previously established co-primary endpoints of myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index.Shares of the company were up 9% in Tuesday's premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4588","RCKT","LABU","RCKT.AU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658122609","title":"Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2658122609","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658122609?lang=en_us&edition=fundamental","pubTime":"2026-08-12 01:36","pubTimestamp":1786469782,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals' (RCKT) Q2 update confirmed its programs are on track, with management expecting regulatory updates on RP-A501 for Danon disease and RP-A601 for PKP2-ACM in H2, Wedbush Securiti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2298064838.USD","LU1861214812.USD","LU2238339852.HKD","ACM","LU1939255532.USD","BK4139","LU0124676726.USD","RCKT.AU","LU2360107325.USD","RCKT","BK4516","LU2308191902.HKD","LU1861219969.SGD","LU0187121727.USD","LU0689626769.HKD","BK4129","LU2244417387.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RCKT.AU\",params:#limit:6,delay:true,,,undefined,":[]}}